Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Stewart Bieler et al.|The Lancet|2023Cited by 264
Collecting duct–specific knockout of endothelin-1 causes hypertension and sodium retentionDowhan Ahn, Donald E. Kohan|Journal of Clinical Investigation|2004Cited by 248